Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30833070 | 1.00 | GRM5 (0.54) | GRM5NPC1RAB9ASMN1; SMN2FFAR1 | |
| Hydrochloric Acid SCHEMBL4309309 | 0.98 | GRM5 (0.53) | GRM5NPC1RAB9ASMN1; SMN2FFAR1 | |
| SCHEMBL14129682 | 0.88 | GRM5 (0.53) | GRM5HDAC6 | |
| SCHEMBL31673355 | 0.82 | GRM5 (0.58) | GRM5CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14129684 | 0.81 | GRM5 (0.46) | GRM5HDAC6 | |
| SCHEMBL12353122 | 0.80 | GRM5 (0.59) | GRM5 | |
| SCHEMBL24230073 | 0.80 | GRM5 (0.54) | GRM5SMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL12017612 | 0.80 | GRM5 (0.50) | GRM5ALDH1A1 | |
| SCHEMBL4710109 | 0.80 | GRM5 (0.55) | GRM5 | |
| SCHEMBL4147154 | 0.79 | MCHR1 (0.53) | GRM5APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040994-B2 | Cobalt complexes, process for preparation and use thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2021-06-22 | — | — | US | disclosed |
| US-20200223880-A1 | COBALT COMPLEXES, PROCESS FOR PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2020-07-16 | — | — | US | disclosed |
| US-9981043-B2 | Analgesic conjugates | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981043-B2 | Analgesic conjugates | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2018-05-29 | — | — | US | disclosed |
| US-20150374836-A1 | ANALGESIC CONJUGATES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150374836-A1 | ANALGESIC CONJUGATES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2015-12-31 | — | — | US | disclosed |
| WO-2014124317-A1 | ANALGESIC CONJUGATES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-08-14 | — | — | WO | disclosed |
| US-7531541-B2 | Partial mGluR5 antagonists for treatment of anxiety and CNS disorders | VANDERBILT UNIVERSITY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20070208028-A1 | Partial mGluR5 antagonists for treatment of anxiety and CNS disorders | VANDERBILT UNIVERSITY | 2007-09-06 | — | — | US | disclosed |
| WO-2007035823-A2 | PARTIAL MGLUR5 ANTAGONISTS AND METHODS OF USE THEREOF | MOLECULAR NEUROIMAGING, LLC (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374836-A1 | ANALGESIC CONJUGATES | OPRL1, OPRK1, GRM5 | GRM5 3/4885NPC1 2233/4885RAB9A 1896/4885 |
| US-20200223880-A1 | COBALT COMPLEXES, PROCESS FOR PREPARATION AND USE THEREOF | MAPT, PSEN1, PSEN2 | GRM5 1926/4885NPC1 126/4885RAB9A 2288/4885 |
| US-20070208028-A1 | Partial mGluR5 antagonists for treatment of anxiety and CNS disorders | GRM5, GRIK5, GRM1 | GRM5 1/4885NPC1 1094/4885RAB9A 967/4885 |
| US-11040994-B2 | Cobalt complexes, process for preparation and use thereof | MAPT, PSEN1, PSEN2 | GRM5 1926/4885NPC1 126/4885RAB9A 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.